Our results indicate that salirasib elicits a dose- and time-dependent growth inhibitory effect in human HCC cell lines, related to inhibition of both EGF- and IGF-induced cell proliferation, and to a lesser extent to induction of apoptosis. Here, EGF is linked to hepatocellular carcinoma.